CellScape Corporation

CellScape Corporation is a privately held company based in Newark, California. Founded in 2008, the company focuses on developing and providing comprehensive prenatal genetic testing solutions. CellScape employs 19 individuals. Their flagship product, Clarity Prenatal Genetic test, aims to analyze fetal DNA collected from maternal blood samples. The Clarity test utilizes chromosomal microarray analysis (CMA) to detect aneuploidies, pathogenic structural rearrangements, and clinically relevant copy number variants (CNVs) associated with genetic disorders. Unique to CellScape's approach is the use of fetal nucleated red blood cells, sourced from maternal circulation, offering a non-invasive alternative to conventional prenatal genetic testing procedures. Clarity Prenatal Genetic test targets a specific set of known genetic disorders, providing valuable insights for expectant parents. Although CellScape ceased operations in 2014, you can find further information about the company's past endeavors and technologies on their website, cellscapecorp.com.